LungLife AI, Inc (DI)

(LLAI)
Sector: Pharmaceuticals & Biotechnology
9.00p
0.00p 0.00
Last updated: 11:00:00

Director dealings

Trade date Director Volume / Price Trade value Trade type
14/08/2023 David Mark Anderson 12,123 @ 69.84p £8,466.70 Buy
14/08/2023 Paul Carmelo Pagano 12,123 @ 69.84p £8,466.70 Buy
02/11/2022 Paul Carmelo Pagano 5,000 @ 130.00p £6,500.00 Buy
08/07/2021 Andrew Norman Boteler 5,681 @ 176.00p £9,998.56 Placing
08/07/2021 Gordon Roy Davis 14,204 @ 176.00p £24,999.04 Placing

Director shareholdings

Name Holding Percent
David Mark Anderson 17,123 0.00%
Paul Carmelo Pagano 17,123 0.00%
Gordon Roy Davis 14,204 0.00%
Andrew Norman Boteler 5,681 0.00%

Major shareholders

Institution name Holding Percent
Killik & Co. 25,480,790 4.45%
Simon Raab 4,148,293 16.30%
Unicorn Asset Management 3,907,142 12.74%
Lombard Odier 2,911,220 9.50%
Mount Sinai 2,469,842 9.70%
Octopus Investments Ltd 1,968,750 7.73%
Syno Ventures Master Fund, L.P. 1,673,668 6.60%
Frederick W. Gluck 1,530,596 6.00%
Livzon Pharmaceutical Group, Inc. 1,347,653 5.30%
Investec Wealth & Investment Limited 1,265,289 4.96%
Accord Data Holdings Limited 954,048 3.70%